ERBB2 and prostate cancer: However, the phosphorylated tyrosine 1248 of Her-2 was associated with BCR, suggesting that IHC evaluation of the phosphorylated form is better than the standard Her-2 test, which is not clinically used for prostate cancer patients because of a lack of reliability and association with outcome.